{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:47:58Z","timestamp":1790740078333,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T00:00:00Z","timestamp":1492128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,8,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Telomerase activity in leukemic blasts frequently is increased among patients with high\u2010risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of human telomerase reverse transcriptase (hTERT)\u2010expressing autologous dendritic cells (hTERT\u2010DCs) in adult patients with AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>hTERT\u2010DCs were produced from patient\u2010specific leukapheresis, electroporated with an mRNA\u2010encoding hTERT and a lysosomal\u2010targeting sequence, and cryopreserved. A total of 22 patients with a median age of 58 years (range, 30\u201075 years) with intermediate\u2010risk or high\u2010risk AML in first or second complete remission (CR) were enrolled. hTERT\u2010DCs were generated for 24 patients (73%). A median of 17 intradermal vaccinations (range, 6\u201032 intradermal vaccinations) containing 1\u00d710<jats:sup>7<\/jats:sup> cells were administered as 6 weekly injections followed by 6 biweekly injections. A total of 21 patients (16 in first CR, 3 in second CR, and 2 with early disease recurrence) received hTERT\u2010DCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>hTERT\u2010DCs were well tolerated with no severe toxicities reported, with the exception of 1 patient who developed idiopathic thrombocytopenic purpura. Of the 19 patients receiving hTERT\u2010DCs in CR, 11 patients (58%) developed hTERT\u2010specific T\u2010cell responses that primarily were targeted toward hTERT peptides with predicted low human leukocyte antigen (HLA)\u2010binding affinities. With a median follow\u2010up of 52 months, 58% of patients in CR (11 of 19 patients) were free of disease recurrence at the time of their last follow\u2010up visit; 57% of the patients who were aged \u226560 years (4 of 7 patients) also were found to be free of disease recurrence at a median follow\u2010up of 54 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The generation of hTERT\u2010DCs is feasible and vaccination with hTERT\u2010DCs appears to be safe and may be associated with favorable recurrence\u2010free survival. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:3061\u201372.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30696","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T13:32:43Z","timestamp":1492176763000},"page":"3061-3072","source":"Crossref","is-referenced-by-count":94,"title":["Immune responses and long\u2010term disease recurrence status after telomerase\u2010based dendritic cell immunotherapy in patients with acute myeloid leukemia"],"prefix":"10.1002","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-3988","authenticated-orcid":false,"given":"Hanna J.","family":"Khoury","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert H.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Blum","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Ohio State University Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Stiff","sequence":"additional","affiliation":[{"name":"Department of Medicine Loyola University Maywood Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Elias","sequence":"additional","affiliation":[{"name":"Geron Corporation Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane S.","family":"Lebkowski","sequence":"additional","affiliation":[{"name":"Asterias Biotherapeutics Inc Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Reddy","sequence":"additional","affiliation":[{"name":"Geron Corporation Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Asterias Biotherapeutics Inc Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sen","sequence":"additional","affiliation":[{"name":"Asterias Biotherapeutics Inc Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward D.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Asterias Biotherapeutics Inc Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey C.","family":"Case","sequence":"additional","affiliation":[{"name":"Asterias Biotherapeutics Inc Menlo Park California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Department of Oncology Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.11.030"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0178"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.01.004"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1268"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.07.002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2977"},{"key":"e_1_2_8_9_1","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high\u2010dose cytarabine with mitoxantrone instead of standard\u2010dose cytarabine with daunorubicin and 6\u2010thioguanine: a randomized trial by the German AML Cooperative Group","volume":"93","author":"Buchner T","year":"1999","journal-title":"Blood."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2003.1.331","article-title":"Immunotherapy of hematologic malignancy","author":"Heslop HE","year":"2003","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"e_1_2_8_12_1","first-page":"259","article-title":"Vaccination with the PR1 leukemia\u2010associated antigen can induce complete remission in patients with myeloid leukemia","volume":"104","author":"Qazilbash MH","year":"2004","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0678-1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.9.2315.bloodjournal8592315"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20394"},{"key":"e_1_2_8_16_1","first-page":"799","article-title":"Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation\u2010inducing agents","volume":"2","author":"Zhang W","year":"1996","journal-title":"Clin Cancer Res."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2000.0339"},{"key":"e_1_2_8_18_1","first-page":"619","article-title":"Clinical implications of telomerase activity levels in acute leukemia","volume":"3","author":"Ohyashiki JH","year":"1997","journal-title":"Clin Cancer Res."},{"key":"e_1_2_8_19_1","first-page":"610","article-title":"Telomerase activity and telomerase length in acute and chronic leukemia, pre and post\u2010ex vivo culture","volume":"60","author":"Engelhardt M","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_8_20_1","first-page":"307","article-title":"Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities","volume":"90","author":"Hartmann U","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0620-3"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0145-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(96)00078-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/32588"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00015-3"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1592"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000171292.79663.cb"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1323"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.465"},{"key":"e_1_2_8_30_1","first-page":"5587","article-title":"Efficient presentation of known HLA class II\u2010restricted MAGE\u2010A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II\u2010associated invariant chain peptide","volume":"63","author":"Bonehill A","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0196-52"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11405"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3894"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO;2-J"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1669"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl072"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-328"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0120"},{"key":"e_1_2_8_39_1","first-page":"5041","article-title":"Enhanced induction of telomerase\u2010specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product","volume":"62","author":"Su Z","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/79519"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.6.3798"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04952.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(09)01202-4"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68395"},{"key":"e_1_2_8_46_1","first-page":"e76698","article-title":"Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1\u2010like effectors by a Toll\u2010like receptor\u2010activated dendritic cell vaccine","volume":"8","author":"Lee MK","year":"2013","journal-title":"PLoS One."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14320"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0772"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S3968"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.11.010"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:32:32Z","timestamp":1760297552000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":50,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,8,15]]}},"alternative-id":["10.1002\/cncr.30696"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30696","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,14]]}}}